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Atherosclerotic vascular disease manifests as a progressive narrowing of the vessel wall, and underlies coronary artery disease (CAD) and cerebrovascular disease. With consequences such as myocardial infarction and stroke, atherosclerosis remains the most frequent cause of death in the western world. While a strong heritable component is undisputed, the molecular inflammatory and immune mechanisms in the evolution of the disease are still not fully understood. By using both animal models of disease (foremost genetically manipulated mice) as well as human tissue, and more recently by employing unbiased approaches to discover genetic loci predisposing to disease development, investigators have revealed a complex picture of multilayered cellular processes and molecular mechanisms. Here we highlight the current view on atherosclerosis and provide an updated account of the critical factors involved in disease development, as illustrated by various prototypic examples. In brief, the response-to-injury hypothesis of Russell Ross introduced the notion that monocyteendothelial interactions give rise to foam cells and growth factor induced smooth muscle cell (SMC) proliferation, triggering lesion formation. 1 Our understanding of the atherogenic process has been considerably refined by the appreciation of subendothelial ApoB lipoprotein retention containing low density lipoprotein (LDL) in the vessel wall under conditions of elevated concentrations of circulating cholesterol. This may predominantly occur at predilection sites with disturbed flow, for example, at branch points of vessels, where increased endothelial turnover and structural changes in elastins and proteoglycans occur, which permit subendothelial accumulation of LDL. In the intima, LDL particles are prone to modifications by reactive oxygen species or enzymes such as myeloperoxidase or lipoxygenases released from inflammatory cells. These oxidised lipids (oxLDL) further trigger the expression of adhesion molecules which contribute to intimal leucocyte recruitment. While early 'fatty streak' lesions mostly comprise lipid laden, monocyte derived, macrophage-like foam cells, the continued accumulation of different leucocyte subsets, their apoptotic cell death, together with the collection of debris and cholesterol crystals in the vessel wall, leads to the formation of a necrotic core. Collagen and SMCs can form a fibrous cap covering the lesion.
Classical risk factors for atherosclerosis include hypertension (which can increase arterial wall tension and lead to disturbed repair processes), the pressor hormone angiotensin II system (which can alter endothelial function, smoking, diabetes), and cholesterol metabolism. Clinical manifestations arise when flow limiting stenoses occur that cause tissue ischaemia, or when thrombi form that either result in emboli or lead to the occlusion of the vessel. One of the conundrums that remains to be elucidated is the fact that thrombotic events frequently are not observed at the sites of the most severe arterial narrowing, but occur as a consequence of a thinning of the fibrous cap, for example, by inflammatory proteases or when being replaced with infiltrating inflammatory cells. The identification and diagnosis of such processes will therefore be a major objective in future research. 2 3 
LIPID TRIGGERED INFLAMMATION IN ATHEROGENESIS
An intriguing recent finding is the presence of small cholesterol crystals in human and mouse atherosclerotic lesions. These crystals appear to be associated with lesional macrophages, accumulate in subendothelial and necrotic areas, and promote atherogenesis by activating the NLRP3 inflammasome, a pattern recognition receptor platform mediating interleukin 1b (IL1b) secretion via caspase-1, and neutrophil recruitment. 4 Whether these crystals precede monocyte recruitment or are formed within macrophages, and what their functional role is in atherogenesis, remain to be fully elucidated (box 1).
The formation and accumulation of foam cells within the vessel wall is thought to be a key event in atherosclerosis. The uptake of cholesterol entails an array of disadvantageous signalling pathways: differentiating macrophages upregulate scavenger receptors (such as SR-A/B and CD36) that mediate the majority of modified LDL uptake. Their genetic deletion, however, does not affect foam cell or lesion formation, but leads to a reduction in the expression of inflammatory genes and macrophage apoptosis. Interestingly, CD36 cooperates with the toll-like receptor 4 (TLR4) and TLR6 in the inflammatory response of macrophages to atherogenic oxLDL. Sequestered CD36 induces an intracellular CD36-TLR4-TLR6 heteromerisation, which activates NF-kB (nuclear factor k-light-chainenhancer of activated B cells) and chemokine expression, and is similarly seen in proatherogenic TLR4 activation. The importance of TLR mediated signalling in atherosclerosis is furthermore accentuated by a reduction in atherosclerosis in mice, with a genetic deletion of TLR2, TLR4 or the TLR signalling adaptor MyD88.
Intracellular free cholesterol can also cause an induction of endoplasmic reticulum (ER) stress; this may at least be mediated by the combined signalling of CD36 with TLR2-TLR6, and promote oxidative burst and macrophage apoptosis. The importance of lipotoxic ER stress in atherogensis is further highlighted by findings showing that mice with a somatic deficiency in the ER stress effector CHOP display a reduction in macrophage apoptosis and plaque necrosis. Similarly, blocking fatty acid binding protein-4 (aP2) function reduces macrophage apoptosis and atherogenesis by limiting lipotoxic ER stress and reactivation of the de novo lipogenesis and lipid desaturation.
Cholesterol is also integrated into cellular membrane lipid rafts. Defective cholesterol efflux due to deficiency of the ABC transporters ABCA1 and ABCG1 can enhance cholesterol-rich raft formation in haematopoietic stem cells, increasing surface expression of the common IL3 and granulocyte macrophage colony stimulating factor (GM-CSF) receptor b subunit and its downstream signalling, resulting in an enhanced myeloproliferation. Accordingly, mice with ABCA1 and ABCG1 deficient bone marrow showed accelerated atherosclerosis. Myeloproliferation and atherosclerosis could be reversed by promoting cellular cholesterol efflux to high density lipoprotein (HDL), as in ApoA-1-transgenic mice with increased HDL concentrations. 5 Importantly, the inverse relationship between HDL and leucocytosis/atherogenesis confirms human correlation studies. However, HDL not only effects reverse cholesterol transport, and transfers cholesterol from peripheral tissue to the liver for excretion, it has also been shown to exert antiinflammatory actions. However, HDL is a heterogeneous particle with different contents of lipids and proteins, and clinical assays for HDL do not reflect this. Thus, the mere increase in HDL concentrations may not necessarily confer clinical benefit. 3 Interestingly, a high expression of the lipoprotein associated phospholipase A2 (Lp-PLA 2 ), which can be deployed in the intima bound to LDL but is also synthesised by inflammatory cells, can be detected in human vulnerable atherosclerotic lesions. An increased Lp-PLA 2 activity correlates with proatherogenic lipids and cardiovascular risk in humans. Lp-PLA 2 primarily hydrolyses oxidised phospholipids in LDL to generate proinflammatory mediators such as lysophosphatidylcholine (LPC) and oxidised non-esterified fatty acids. Selective inhibition of Lp-PLA 2 with darapladib reduces development of complex CAD in swine, limiting LPC content, lesions with an unstable phenotype and inflammatory gene expression. The LPC derivative lysophosphatidic acid (LPA), which is increased in plaques and serum in hypercholesterolaemia, has similarly been implicated in atherogenesisdfor example, by mediating the activation of and interactions between endothelial cells, monocytes and platelets, and promoting macrophage accumulation and lesion progression in atherosclerosis-prone mice. 2 
CYTOKINES AND CHEMOKINES IN ATHEROSCLEROSIS
A number of pro-and anti-inflammatory cytokines controlling leucocyte recruitment and cell functions determine lesion growth. Among the cytokines upregulated within atherosclerotic lesions, macrophage migration inhibitory factor (MIF) can be detected in endothelial cells and macrophages in response to oxLDL. MIF is critically involved in a number of processes, such as endothelial cell activation, monocyte recruitment, foam cell formation, SMC migration and extracellular matrix destabilisation, exerting pro-inflammatory and proatherogenic functions. The importance of MIF during atheroprogression was strikingly demonstrated in studies using an MIF specific antibody that afforded true regression of established atherosclerotic lesions (box 2). 6 As another example, type I interferons (IFNs) have been implicated in atherogenesis. Treatment of atherosclerosis prone mice with IFNb increases lesion size, whereas myeloid deficiency of IFNAR1, the receptor for type I IFNs, attenuates atherogenesis, macrophage accumulation and necrotic core formation. These effects are at least in part mediated by the upregulation of CCL5 production Box 1 Atherosclerotic vascular disease: a lipid driven, inflammatory disease < Macrophage scavenger receptors cooperate with toll-like receptors to respond to lipids to drive inflammation and atherogenesis. < Cholesterol can cause endoplasmic reticulum stress ('lipotoxic ER stress') that leads to macrophage apoptosis and plaque necrosis. < Cholesterol crystals associated with lesional macrophages accumulate in necrotic areas and promote atherogenesis by activating the NLRP3 inflammasome and recruiting neutrophils. < Cholesterol-rich lipid rafts in the cell membrane can enhance cytokine receptor signalling driving myeloproliferation; cholesterol efflux from these rafts to high density lipoprotein (HDL) protects against atherosclerosis. < Oxidised low density lipoprotein (LDL) can be hydrolysed by lipoprotein associated phospholipase A2 to generate proinflammatory mediators, such as lysophosphatidylcholine (LPC) or its derivate lysophosphatidic acid (LPA) that drive inflammatory gene expression.
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by macrophages, increasing CCR5 mediated monocyte recruitment. This may also reflect the correlation between upregulated type I IFN signalling and CCL5 expression in advanced human lesions. Atherogenic recruitment of leucocytes involves sequential rolling, firm adhesion, lateral migration and transendothelial diapedesis and is controlled by chemokines (chemotactic cytokines), classified according to their conserved cysteine residues, and their corresponding G protein coupled receptors. 7 In recent years a number of leucocytes were identified as being recruited to the vessel wall during atherosclerosis, including neutrophils, monocytes and T cells, as well as B cells, dendritic cells (DCs) and mast cells. 8 Given the diversity of these cell subsets, signature combinations of chemokines have been perceived to confer robustness and specificity. The combined action of chemokines in leucocyte recruitment is illustrated by the chemokines CCL5 and CXCL4, which are deposited by platelets or platelet derived microparticles during their transient P-selectin mediated interactions on inflamed endothelium, where they promote atherogenic monocyte arrest. CXCL4 amplifies CCL5 triggered monocyte arrest, and inhibition of this synergism by blocking CCL5-CXCL4 heteromerisation reduces atherogenesis in hyperlipidaemic mice. 9 In mice, monocytes can be subdivided into at least two different subsets. Classical Ly6C high cells dominate hyperlipidaemia induced monocytosis and invade plaques by employing the chemokine receptors CCR2, CCR5 and CX3CR1, whereas entry of patrolling Ly6C low monocytes occurs less frequently and seems to rely on CCR5. Genetic deletion of CCL2 and CX3CR1 or CCR2 and CX3CL1 decreases atherosclerosis compared with single deficiencies in these proteins, which is attributable to both attenuated hyperlipidaemia associated blood monocytosis and reduced macrophage accumulation, further highlighting the combined action of chemokines in cell recruitment.
In addition, temporal patterns of chemokine expression during distinct phases control the process of atherogenesis. For example, the genetic deletion of CCR2 in mice did not prevent early lesion formation in the abdominal aorta but rather limited late stage plaque formation and monocyte infiltration in the aortic root. In contrast, mouse CXCR3 deficiency primarily delayed early atherosclerosis by attenuating recruitment of T helper 1 (T H 1) T cells. The lack of the CCL5 receptor CCR5 in somatic or blood cells reduced plaque formation in mice at later stages, upregulated systemic IL10 and downregulated interferon g (IFNg), reflecting an attenuated T H 1-type response. 7 Aside from the functions of chemokines in recruitment, the absence of CX3CR1 
À/À mice, emphasising the homeostatic functions of this axis in atherosclerosis. 10 Conversely, deficiency or antibody blockade of DC derived CCL17 in hyperlipidaemic mice reduced atheroprogression by expanding T reg cells, whereas CCL17 expression in DCs restricted T reg cell maintenance to promote atherosclerosis, identifying CCL17 as a central regulator of T reg cell homeostasis.
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LEUCOCYTES INVOLVED IN ATHEROGENESIS Monocytes/macrophages
While monocytes/macrophages predominate the inflammatory cell infiltrate in atherosclerosis and have been discussed in detail elsewhere, 12 new cellular players have recently been uncovered in recent years, with hitherto underappreciated cell populations emerging as contributors to disease development. In addition, the important role of different subtypes of activated macrophages has become evident in diet induced obesity and atherosclerosis, where the activation state of resident and newly recruited macrophages may shift from an alternatively activated M2 phenotype (polarised through IL4/IL13) to a classical proinflammatory M1 phenotype (responding to IFNg) to exacerbate disease. 8 
Neutrophils
Polymorphonuclear leucocytes (neutrophils) have been detected in aortic fatty streak lesions of primates and correlate with the incidence and severity of CAD, and have been localised to human and mouse atherosclerotic lesions. Convincing evidence for a proatherogenic role of neutrophils has recently been disclosed in the initial phase of atherosclerosis in mice. 13 It was furthermore demonstrated that hyperlipidaemia triggers neutrophilia by stimulating granulopoiesis and bone marrow egress. Moreover, a disturbed lipid balance facilitates their recruitment to lesions, as shown in bone marrow ABC transporter deficient mice, which showed pronounced neutrophil infiltration upon peripheral inflammatory signals. Neutrophils can subsequently promote monocyte recruitment. Furthermore, a link between neutrophils and coagulation has been provided by Box 2 Cytokines and chemokines in atherosclerosis: functions in cell recruitment and beyond < Inflammatory cytokines, such as macrophage migration inhibitory factor (MIF) and type I interferons, and co-stimulatory molecules can critically promote inflammation and atherogenesis. < Signature combinations of chemokines and their heteromers act in a spatialtemporal manner to recruit leucocyte subsets via specific chemokine receptors, eg, CCL5/CXCL4 via CCR5. < Chemokines in addition control post-recruitment cell homeostasis, eg, CX3CL1/CX3CR1 drives monocyte survival; the chemokine CCL17 restricts the maintenance of Tregs.
evidence that neutrophil serine proteases along with externalised nucleosomes promote intravascular thrombus growth in vivo by enhancing tissue factor and factor XII dependent coagulation through proteolysis of the tissue factor pathway inhibitor. The continued presence of neutrophils in advanced plaques may thus contribute to large vessel thrombosis as a trigger for myocardial infarction and stroke. 2 8 Dendritic cells Mature DCs further accumulate during atheroprogression and cluster with T cells in the shoulder and rupture prone plaque regions. Moreover, aortic CD11c + DCs have been shown to trigger antigen specific T cell proliferation. By sensing atherogenic danger signals and antigen internalisation, DCs may be ideally positioned at the crossroads of innate and adaptive immunity and may be instrumental in orchestrating a switch from tolerance to adaptive immunity activation.
14 Recently, distinct DC subsets with opposing functions have been discovered. In advanced plaques, CCL17 expression by mature DCs restricts T reg cell expansion and sustains atherosclerosis, identifying the control of T reg cell homeostasis as an effector mechanism of CCL17 + DCs in atherogenesis. 11 In contrast, aortic CD103 + DCs are associated with the protection of atherosclerosis and the maintenance of T regs . 15 
T cells
Atherosclerotic plaques feature a clonal expansion of memory effector T cells, indicating antigen specific reactions, and can also confer lesion formation upon reconstitutive transfer. The importance of antigen specific immune responses in atherogenesis is widely acknowledged. Moreover, activation of CD8 + T cells against an SMC expressed artificial antigen exacerbates atherosclerosis in hyperlipidaemic mice. Ldlr À/À mice deficient in the major T H 1 differentiating transcription factor T-bet show a reduced lesion size, indicating that atheroprogression is driven by a T H 1-type response and its signature cytokines IFNg, IL12, and IL18. Conversely, numerous studies have established atheroprotective effects mediated by T reg cell subsets and their products transforming growth factor b (TGFb) and IL10. In contrast, data for T H 2 and T H 17 cells are less conclusive and partially contradictory.
B cells
Bone marrow B cell deficiency or splenectomy aggravates atherosclerosis in mice, whereas splenic B cell transfer mediates protection in splenectomised recipients. Accordingly, deficiency in bone marrow IL5, a cytokine that expands natural B1 cells, increases atherosclerosis and reduces oxLDL reactive immunoglobulin M (IgM) values. Although oxLDL specific IgG titres correlate with CAD, oxLDL specific IgM titres are associated with atheroprotection, whichdlike regressiondcan be conferred by recombinant antibodies to oxLDL in mice. Notably, depletion of conventional B2 cells ameliorates atherosclerosis, whereas transfer of B2 but not B1 cells promotes atherosclerosis, confirming subset specific effects.
MicroRNAs IN ATHEROGENESIS
microRNAs (miRNAs) that post-transcriptionally regulate gene expression may in addition add another dimension in the regulation of cell differentiation and functions. In addition, miRNAs have emerged as important post-transcriptional regulators of lipid metabolism, and represent a new class of targets for therapeutic intervention. Recently, microRNA-33a and b (miR-33a/b) were discovered as key regulators of metabolic programmes including cholesterol and fatty acid homeostasis. These intronic microRNAs are embedded in the sterol response element binding protein genes, which code for transcription factors that coordinate cholesterol and fatty acid synthesis. By repressing a variety of genes involved in cholesterol export and fatty acid oxidation, miR-33a/b boost cellular sterol concentrations. 16 Indeed, inhibition of miR-33 by antagomirs in mice or non-human primates can promote reverse cholesterol transport to raise HDL concentrations and possibly mediate regression of atherosclerosis.
The analysis of miRNA expression patterns in arterial lesions and atherosclerotic plaques has revealed fundamental changes in the miR signature comprising many different miRs. Moreover, single miRNAs have been pinpointed to exert a significant impact on neointimal lesion formation, for example, miR-143 and miR-145, and studies addressing the function of miRNAs in the development of atherosclerosis are ongoing. 17 Recent miRNA profiling studies further revealed that circulating concentrations of vascular derived microRNAs, including miR-126, were reduced in individuals with CAD. 2 Interestingly, miR-126 or miR-126 carrying endothelial apoptotic bodies have been identified as being atheroprotective in mice, promoting CXCR4 dependent mobilisation and
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Heart 2012;98:1600-1606. doi:10.1136/heartjnl-2012-301761lesional incorporation of angiogenic progenitor cells. By repressing RGS16, miR-126 unleashes autoregulatory CXCR4 signalling and increases endothelial production of CXCL12, a mediator of stem cell mobilisation and homing. 18 The recruitment of such circulating (or locally residing) cytokine releasing progenitor cells may support endothelial regeneration or modulate inflammation, but may contribute to neovascularisation in advanced plaque stages. 8 These findings support the development of microRNA antagonists as potential therapeutic agents for the treatment of dyslipidaemia, atherosclerosis, and related metabolic disease.
MICROBIOTIC FLORA IN THE GUT
The intestinal microbiotic flora performs essential functions in nutrient processing and assists host immune responses, but it has also been linked to metabolic and immune disorders, prompting studies of its relation to human disease. A recent metabolomics approach identified the dietary lipid phosphatidylcholine and its metabolites choline, betaine, and trimethylamine N-oxide (TMAO) as risk factors for cardiovascular disease. In mice, a choline-rich diet increased TMAO values and atherosclerosis, depending on gut flora activity, as shown by broad spectrum antibiotic treatment. Although earlier antibiotic trials failed to reduce event rates in humans with CAD, specific targeting of bacterial species responsible for choline metabolism using selective antibiotics or probiotics might have therapeutic value for cardiovascular disease.
19
Detailed analysis of the relations between gut microbiota, host metabolism, and atherosclerosis may allow for subtle microbiota manipulation as a new way to modulate lipid metabolism and treat CAD.
THERAPEUTIC OPTIONS AGAINST ATHEROSCLEROSIS
The high incidence of atherosclerosis related cardiovascular disease and CAD imposes an enormous burden on healthcare systems. The established therapeutics against atherosclerosis are largely focused on alleviating hypertension and hyperlipidaemia or controlling haemostasis to prevent thrombotic complications (table 1) . 2 20 Treatment with statins for secondary prevention in patients with CAD can result in a pronounced risk reduction, which correlates with lowering of LDL cholesterol. Statins exert a pleiotropy of antiinflammatory actions, improve endothelial function and reduce plaque lipids and thrombogenicity, thereby limiting atheroprogression and increasing plaque stability. Aggressive lipid lowering by high dose atorvastatin decreases high sensitivity C reactive protein (hs-CRP) serum concentrations and causes regression of atheromas. This clinical benefit is extended to primary prevention in patients with LDL cholesterol concentrations <130 mg/dl (<3.4 mmol/l) but elevated hs-CRP, where rosuvastatin significantly reduces major cardiovascular event rates, with reductions in both LDL cholesterol and hsCRP indicating successful treatment. In acute coronary syndrome (ACS), aggressive statin treatment also lowered the incidence of primary end points including myocardial infarction, with the most substantial benefit in patients with declines in both LDL cholesterol and CRP. In statin treated patients with low HDL cholesterol, extended release of nicotinic acid (niacin) may shift the lipid 
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